P. Abram

653 total citations
10 papers, 438 citations indexed

About

P. Abram is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, P. Abram has authored 10 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in P. Abram's work include Breast Cancer Treatment Studies (7 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (5 papers). P. Abram is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (5 papers). P. Abram collaborates with scholars based in United Kingdom, Austria and United States. P. Abram's co-authors include Anthony Howell, Isaiah W. Dimery, J.F.R. Robertson, Mikhail Lichinitser, Richard Elledge, Toru Watanabe, C. Kent Osborne, Emilio Bajetta, Charles Morris and Alan Webster and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

P. Abram

10 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Abram United Kingdom 5 274 253 174 151 71 10 438
J R Borst United States 5 253 0.9× 145 0.6× 115 0.7× 139 0.9× 86 1.2× 10 423
E. Jane Macaskill United Kingdom 12 329 1.2× 232 0.9× 130 0.7× 244 1.6× 133 1.9× 18 533
SE Come United States 8 429 1.6× 355 1.4× 249 1.4× 288 1.9× 103 1.5× 19 652
M Dowsett United Kingdom 9 277 1.0× 321 1.3× 63 0.4× 165 1.1× 239 3.4× 11 515
Juliette Murray United Kingdom 11 312 1.1× 275 1.1× 90 0.5× 276 1.8× 137 1.9× 27 532
Carol M. Dutkowski United Kingdom 9 287 1.0× 188 0.7× 87 0.5× 86 0.6× 329 4.6× 14 544
Amanda Beyer United States 12 314 1.1× 311 1.2× 193 1.1× 219 1.5× 317 4.5× 17 661
Ian Farmer United Kingdom 10 255 0.9× 280 1.1× 113 0.6× 107 0.7× 248 3.5× 12 531
Mikael von Euler Sweden 6 255 0.9× 337 1.3× 137 0.8× 257 1.7× 108 1.5× 12 531
William N. Harwin United States 7 488 1.8× 535 2.1× 259 1.5× 395 2.6× 129 1.8× 21 856

Countries citing papers authored by P. Abram

Since Specialization
Citations

This map shows the geographic impact of P. Abram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Abram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Abram more than expected).

Fields of papers citing papers by P. Abram

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Abram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Abram. The network helps show where P. Abram may publish in the future.

Co-authorship network of co-authors of P. Abram

This figure shows the co-authorship network connecting the top 25 collaborators of P. Abram. A scholar is included among the top collaborators of P. Abram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Abram. P. Abram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Marla, Sekhar, David Dodwell, A. Skene, et al.. (2010). 94 A multicentre audit of HER2 positive Early Breast Cancers and the reasons why patients do not receive trastuzumab therapy. European Journal of Cancer Supplements. 8(3). 85–86. 2 indexed citations
2.
Marla, Sekhar, David Dodwell, A. Skene, et al.. (2010). HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.. Journal of Clinical Oncology. 28(15_suppl). 668–668. 3 indexed citations
3.
Doughty, Julie, James Mansell, I. Monypenny, et al.. (2009). 0188 Distant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres. The Breast. 18. S66–S66. 6 indexed citations
4.
Mansell, James, et al.. (2009). The effect of quantitative oestrogen receptor expression on recurrence in postmenopausal women with early stage breast cancer.. Cancer Research. 69(2_Supplement). 1131–1131. 1 indexed citations
5.
Mansell, James, Ian Monypenny, Anthony Skene, et al.. (2008). Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment. 117(1). 91–98. 65 indexed citations
6.
Abram, P., et al.. (2005). Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Annals of Oncology. 17(2). 200–204. 63 indexed citations
7.
Howell, Anthony & P. Abram. (2005). Clinical development of fulvestrant (‘Faslodex’). Cancer Treatment Reviews. 31. S3–S9. 18 indexed citations
8.
Abram, P., Nicolaì Maass, Daniel Rea, Sérgio D. Simon, & Guenther G. Steger. (2005). Case studies of fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Treatment Reviews. 31. S17–S25. 1 indexed citations
9.
10.
O’Neill, Kim L., P. Abram, B. M. Hannigan, & Greg J. McKenna. (1987). Elevated serum and mononuclear leukocyte thymidine kinase activities in patients with cancer.. PubMed. 80(9). 264–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J R Borst Breakdown of academic impact, for papers by E. Jane Macaskill Breakdown of academic impact, for papers by SE Come Breakdown of academic impact, for papers by M Dowsett Breakdown of academic impact, for papers by Juliette Murray Breakdown of academic impact, for papers by Carol M. Dutkowski Breakdown of academic impact, for papers by Amanda Beyer Breakdown of academic impact, for papers by Ian Farmer Breakdown of academic impact, for papers by Mikael von Euler Breakdown of academic impact, for papers by William N. Harwin
Rankless by CCL
2026